ARTICLE | Finance
Deerfield pays Tribute to Pozen
Why Deerfield is giving war chest to Pozen to buy Tribute and more
June 15, 2015 7:00 AM UTC
Deerfield is betting $300 million on the combination of a Canadian cardiovascular specialty pharma with a U.S. biotech that has new management, a late-stage cardio asset and a royalty stream.
The firm is backing a deal by Pozen Inc. (NASDAQ:POZN) to buy Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF; TSX-V:TRX) for $146 million...